Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Simple Summary Renal cell carcinoma is particularly characterized by its high
vascularization and dense immune cells infiltration. The angiogenesis blockade in …

Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several
genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very …

Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

Lack of appropriate models that recapitulate the complexity and heterogeneity of urological
tumours precludes most of the preclinical reagents that target urological tumours from …

Molecular targeted therapy is a standard treatment for patients with advanced renal cell
carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for …

A number of novel anticancer drugs have been developed in recent years. However, the
mortality of cancer patients remains high because of the emergence of drug resistance. It …

Acquired resistance and intrinsic to sorafenib therapy represents a major hurdle in
improving the management of advanced hepatocellular carcinoma (HCC), which has been …

Most patients who initially respond to treatment with the multi–tyrosine kinase inhibitor
sunitinib eventually relapse. Therefore, developing a deeper understanding of the …